Kennedy Capital Management LLC Acquires 172,648 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Kennedy Capital Management LLC lifted its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 29.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 752,580 shares of the medical device company’s stock after acquiring an additional 172,648 shares during the quarter. AtriCure makes up 0.5% of Kennedy Capital Management LLC’s investment portfolio, making the stock its 24th largest position. Kennedy Capital Management LLC owned approximately 1.54% of AtriCure worth $22,999,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ATRC. Captrust Financial Advisors bought a new position in shares of AtriCure during the 3rd quarter worth $230,000. State Street Corp lifted its holdings in AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after purchasing an additional 63,002 shares in the last quarter. Wellington Management Group LLP lifted its holdings in AtriCure by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company’s stock worth $43,291,000 after purchasing an additional 6,045 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in AtriCure during the 3rd quarter worth about $614,000. Finally, Geode Capital Management LLC lifted its holdings in AtriCure by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock worth $32,326,000 after purchasing an additional 32,676 shares in the last quarter. Institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

Shares of AtriCure stock opened at $33.10 on Thursday. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The stock’s fifty day moving average is $36.34 and its 200 day moving average is $34.23. The stock has a market cap of $1.62 billion, a P/E ratio of -34.84 and a beta of 1.65. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. dropped their price objective on AtriCure from $51.00 to $46.00 and set an “overweight” rating on the stock in a report on Thursday, March 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $60.00 price target on shares of AtriCure in a report on Monday, February 10th. Stifel Nicolaus raised their price target on AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 13th. BTIG Research reaffirmed a “buy” rating on shares of AtriCure in a report on Thursday, March 27th. Finally, Canaccord Genuity Group lowered their price target on AtriCure from $66.00 to $52.00 and set a “buy” rating on the stock in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, AtriCure currently has a consensus rating of “Moderate Buy” and an average target price of $49.44.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 6,100 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the sale, the director now directly owns 17,828 shares of the company’s stock, valued at $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.20% of the stock is owned by insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.